10 nəticələr
The effect of (-)eburnamonine, papaverine and UDP-glucose intracarotid perfusion has been evaluated in the brain of beagle dogs during various conditions of cerebral damage (hypoxia, hypoxia plus incomplete ischaemia, hypoxia plus complete ischaemia), and after 3, 15 or 30 min of the post-hypoxic
Using venous infusion (0.25 mg/kg min.), l-eburnamonine decreases the electroencephalographic modifications induced by acute asphyxic anoxia in curarized rats. This activity appears when the total dose administrated before the first asphyxia is approximatively 5 mg/kg. In such conditions, its
The influence of 1-éburnamonine (1-E) and vincamine (Vi) on 2,3-disphosphoglycerate (2,3-DPG) blood level was investigated in awake rats when cyanide (KCN) induced hypoxia was present or not. Used alone, KCN, 1-E and Vi (i.p. route) increased 2,3-DPG blood level. Used with KCN, 1-E or Vi produced a
The synaptosomal fraction obtained from the motor area of the cerebral cortex of normocapnic, normoxic or hypoxic "young adult," "mature" and "senescent" beagle dogs is incubated and analyzed for : ATP, ADP, AMP, creatine phosphate, pyruvate and lactate. The data are compared with those obtained
Synaptosomal preparations from the motor area of the cerebral cortex of normocapnic, normoxic or hypoxic untreated beagle dogs and phenobarbital-, papaverine-, and (-) eburnamonine-treated dogs were incubated for 10 min at 24 degrees C and analyzed for ATP, ADP, AMP creatine phosphate, pyruvate, and
l-Eburnamonine--16-oxoeburnane--assumes experimental cerebral 'oxygenator' and antihypoxic properties which appear more pronounced than those of vincamine. In anesthetized dogs, l-eburnamonine increases the cerebral oxygen supply and the cerebral oxygen consumption, without cerebral vasodilation;
Vinpocetine has been compared with 3 structurally related drugs for activity in protecting mice from hypoxia-induced lethality upon i.p. administration. In order of potency, vinpocetine (ED50 = 16.6 mg/kg), 1-eburnamonine (ED50 = 21.0 mg/kg), vinconate (ED50 approximately 25 mg/kg), and vincamine
The authors described an experimental approach, specially using oral administration, of drugs used in cerebral metabolic insufficiencies and its application to l-eburnamonine (l-EB). Administered orally, l-EB: (1) significantly increased the cerebral consumption of [14C]- deoxyglucose in normoxic
The behaviour of fuels (glycogen, glucose), of glycolytic pathway intermediates (glucose-6-phosphate, pyruvate) and end-product (lactate), as well as the pool of labile phosphates (ATP, ADP, AMP, creatine phosphate) and the energy charge of the brain were studied in the motor area of the cerebral
The effects of a new eburnamenine derivative (3 beta,14 alpha, 16 alpha)-(+/-)-14,15-dihydro-20,21-dinoreburnamenin-14-ol (vindeburnol, RU 24722) on EEG, on brain energy metabolism and on local cerebral blood flow (LCBF) and in different experimental models of cerebral insufficiency were compared